SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ProMetic Life Sciences
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: axial10/13/2017 9:11:00 AM
   of 250
 
Prometic CEO Talks Plasminogen Deficiency

... 'RDR: What did the efficacy data show in those first 10 patients?
—Laurin: There was a 100% response in those 10 patients. It was a remarkable result. Patients walked into that trial with visible lesions or lesions documented by CAT Scan or X-ray. They saw their lesions get resolved, sometimes in hours or within a couple weeks.

The infusion of plasminogen does not restore the plasminogen to 100% but it does restore it to levels that provides enough to digest those lesions. We announced recently that those 10 patients have now competed over 48 weeks of treatment and there were no recurrences of any lesions as well as no adverse events throughout the program. So this is really impressive.

RDR: How is Ryplazim administered?
—Laurin: It is an infusion that initially will be given by a health professional but after 2 or 3 infusions we know that patients or their caregivers can usually administer the product at home. There will be home infusion centers for those who prefer that approach. The frequency of the administration will depend on the patient and their condition. For acute care to remove lesions, infusions every 3 or 4 days will be likely but once the lesions are out, the maintenance treatment needed to prevent lesions from coming back will vary from patient to patient—maybe every second or third week.'

Jim
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News